Cangrelor for Acute Coronary Syndrome (SWAP-6 Trial)

"This clinical trial seeks out 90 individuals between 18 and 75 years old who have been diagnosed with coronary artery disease. To meet the eligibility criteria, they must be suffering from NSTE-ACS (UA or NSTEMI) following PCI; an electrocardiogram displaying cardiac ischemic symptoms can confirm this diagnosis, though a normal reading may also suffice if the attending clinician believes it to demonstrate ACS presentation."

"At present, 16 studies are underway to study Cangrelor. Of these clinical trials, 3 have moved into Stage 3 of testing. Many tests for this treatment are located in Kansas City, Kansas with a total of 515 sites across the US running related research."

"As evidenced by the clinicaltrials.gov page, this research study is actively enrolling participants. This experiment was first announced on February 9th 2021 and underwent an update as recent as October 18th 2022."

"Cangrelor is typically used to address cardiovascular events, although it also shows efficacy in prophylaxis of stent thrombosis, percutaneous coronary intervention and coronary revascularization."

"Given the late-stage nature of this clinical trial, Cangrelor has been assigned a safety score of 3. This rating reflects approval by regulatory authorities and extensive prior data collection."

"Affirmative. Clinicaltrials.gov displays that this study is actively looking for patients to participate and was initially posted on February 9th 2021 with the last update occurring on October 18th 2022. This trial requires 90 people from a single medical centre."

"This clinical trial has set the age criteria from 18 to 75 years old. For younger demographics, there are 394 trials available and for senior citizens 1560 studies have been listed."